Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389573 | 0.98 | CA1 (0.43) | CA1CA2SMYD3TSHRHPGD | |
| SCHEMBL1389439 | 0.98 | CA1 (0.43) | CA1CA2SMYD3TSHRHPGD | |
| SCHEMBL5618655 | 0.91 | CA1 (0.42) | CA1CA2SMYD3TSHRHPGD | |
| SCHEMBL1829452 | 0.82 | L3MBTL1 (0.39) | SMYD3POLBKMT2A | |
| SCHEMBL1389415 | 0.82 | LMNA (0.46) | SMYD3TSHRPOLBCA12CA7 | |
| SCHEMBL1395219 | 0.82 | LMNA (0.46) | SMYD3TSHRPOLBCA12CA7 | |
| SCHEMBL1395247 | 0.82 | LMNA (0.46) | SMYD3TSHRPOLBCA12CA7 | |
| SCHEMBL5022227 | 0.82 | CA1 (0.46) | CA1CA2SMYD3TSHRHPGD | |
| SCHEMBL22482174 | 0.80 | CA1 (0.50) | CA1CA2SMYD3TSHRHPGD | |
| SCHEMBL24767441 | 0.79 | FAAH (0.45) | CA2TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2014-12-04 | — | — | US | disclosed |
| US-8871747-B2 | Urea and thiourea derivatives | TOPOTARGET A/S (DK) | 2014-10-28 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | MCDERMOTT WILL & EMERY LLP (DC) | 2012-01-12 | — | — | US | disclosed |
| EP-2342181-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | Topo Target A/S (DK) | 2011-07-13 | — | — | EP | disclosed |
| EP-2318369-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TopoTarget A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010066709-A1 | NOVEL PYRIDINYL ACRYLAMIDE DERIVATIVES | TOPOTARGET A/S (DK) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010023307-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TOPOTARGET A/S (DK) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009156421-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TOPOTARGET A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009086835-A1 | NOVEL CYANOGUANIDINES | TOPOTARGET A/S (DK) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TST, NAMPT, NNMT | CA1 4533/4885CA2 4675/4885SMYD3 3156/4885 |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TST, NAMPT, NNMT | CA1 4533/4885CA2 4675/4885SMYD3 3156/4885 |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | SUCNR1, NAMPT, NAPRT | CA1 1638/4885CA2 2382/4885SMYD3 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.